Paul Stoffels Entrepreneurial Experience Description of JLABS from Paul Stoffels Related content Related video Correlia presentation Related article Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment. TAGS Entrepreneur JLABS Impact Paul Stoffels
Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.
